Medicxi
SlowingSt Helier, Y9Pharmaceuticals, Biotechnology, EnergyLast fund filed September 2025
3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Medicxi V | September 2025 | Indefinite | $290M | 15 |
| Medicxi IV | May 2022 | Indefinite | $195M | 20 |
| Medicxi Secondary I | September 2020 | $95M | $95M | 18 |
| Medicxi III | June 2019 | Indefinite | $260M | 25 |
| Medicxi Growth I | November 2016 | Indefinite | $22M | 4 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
9 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Kevin JohnsonNot on the current fund | Slowing | None listed | 14 | 1 |
| Christopher PattonNot on the current fund | Quiet | None listed | 0 | 0 |
| David GraingerNot on the current fund | Quiet | None listed | 1 | 0 |
| Francesco De RubertisNot on the current fund | Quiet | Biotech & pharma | 4 | 0 |
| Francois Chesnay | Quiet | None listed | 0 | 0 |
| Giovanni Pericolini | Quiet | None listed | 0 | 0 |
| Giuseppe ZoccoNot on the current fund | Quiet | None listed | 0 | 0 |
| Louisa Blanchet | Quiet | None listed | 0 | 0 |
| Michele OllierNot on the current fund | Quiet | Biotech & pharma | 4 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of Medicxi’s own portfolio companies, based on 14 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Medicxi’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Advent Life Sciences | 1 | Versartis |
| Longitude Capital | 1 | Rivus Pharmaceuticals |
| Samsara Biocapital | 1 | Versartis |
A shared board seat: a company where filings name a Medicxi partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.